Physician profile
Ann E Hanley
NPI 1700961497
$2,632.16
in general payments reported to CMS, 2019-2025
31 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,564 · 2020: $30.57 · 2021: $37.53.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $273.69 | 2019 | |
| Genzyme Corporation | $233.59 | 2019 | |
| Supernus Pharmaceuticals, INC. | $230.47 | 2019 | |
| Biogen, INC. | $221.32 | 2019 | |
| Acadia Pharmaceuticals INC | $186.13 | 2019 | |
| Genentech USA, INC. | $130.67 | 2019 | |
| Arbor Pharmaceuticals, INC. | $102.53 | 2019 | |
| Mdd US Operations, LLC | $95.03 | 2019-2021 | |
| Emd Serono, INC. | $87.51 | 2019 | |
| Alexion Pharmaceuticals, INC. | $87.48 | 2019 | |
| Ucb, INC. | $82.89 | 2019 | |
| Assertio Therapeutics, INC. | $80.20 | 2019 | |
| Sunovion Pharmaceuticals INC. | $77.58 | 2019 | |
| Vertical Pharmaceuticals, LLC | $72.27 | 2019 | |
| Lilly USA, LLC | $71.79 | 2019 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $71.20 | 2019 | |
| Lundbeck LLC | $61.21 | 2019 | |
| Indivior INC. | $61.20 | 2019-2021 | |
| Grifols USA, LLC | $58.50 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $52.69 | 2019 | |
| Akcea Therapeutics, INC. | $51.40 | 2019 | |
| Avanir Pharmaceuticals, INC. | $43.45 | 2019 | |
| Eisai INC. | $37.78 | 2019 | |
| Acorda Therapeutics, INC | $31.26 | 2019 | |
| Csl Behring | $31.07 | 2019 | |
| Alnylam Pharmaceuticals INC. | $20.72 | 2019 | |
| Catalyst Pharmaceuticals, INC. | $18.28 | 2019 | |
| Medtronic Vascular, INC. | $17.19 | 2019 | |
| Kyowa Kirin, INC. | $16.85 | 2019 | |
| Bausch Health US, LLC | $13.94 | 2019 | |
| Portola Pharmaceuticals, LLC | $12.27 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ann Hanley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.